Study Explores Most Cost-Effective Smoking Cessation Methods in Lung Cancer Screening

Why It Matters

The findings give health systems concrete data to align guideline‑recommended cessation services with financial sustainability, accelerating integration into lung‑cancer‑screening pathways.

Key Takeaways

• Eight telehealth sessions + 2‑week NRT cost $3,050 per quit.
• Startup EHR programming cost $131k, dominates initial expenses.
• Operating costs $196k‑$275k, improve with higher patient volume.
• No social‑determinants screening needed for most cost‑effective strategy.
• Findings guide health systems on affordable cessation integration.

Pulse Analysis

Integrating smoking‑cessation services into lung‑cancer‑screening programs has long been a clinical priority, but health‑system leaders often wrestle with the economics of implementation. This study provides a granular cost‑effectiveness framework, separating fixed start‑up investments—chiefly electronic‑health‑record (EHR) algorithms for patient identification—from variable operating expenses such as counseling staff time and nicotine‑replacement therapy (NRT). By quantifying the incremental cost per quit at $3,050, the analysis offers a benchmark that can be compared against other preventive interventions, helping administrators justify budget allocations and negotiate payer contracts.

The research also highlights economies of scale that become apparent as screening volumes rise. Larger health systems can dilute the $131,371 start‑up outlay across more patients, driving down per‑quit costs and making intensive counseling models financially viable. This insight is especially relevant for integrated delivery networks and accountable care organizations that aim to meet US Preventive Services Task Force recommendations while maintaining cost containment. Moreover, the study’s sensitivity analyses underscore the importance of local factors—EHR readiness, wage structures, and payer mix—in shaping real‑world affordability, prompting institutions to tailor rollout strategies to their operational context.

Beyond the immediate financial calculus, the findings have broader implications for public health outcomes. Effective cessation during the screening window can reduce smoking‑related morbidity, lower downstream cancer treatment costs, and improve overall survival rates. As policymakers consider incentive programs and value‑based reimbursement models, evidence of a low‑cost, high‑impact cessation pathway strengthens the case for mandatory integration of these services into lung‑cancer‑screening protocols. Health systems that act now can position themselves as leaders in preventive care while reaping long‑term economic and clinical benefits.